{
    "name": "tisotumab vedotin",
    "comment": "Rx",
    "other_names": [
        "Tivdak",
        "tisotumab vedotin-tftv"
    ],
    "classes": [
        "Antineoplastics",
        "Antimicrotubulars"
    ],
    "source": "https://reference.medscape.com/drug/tivdak-tisotumab-vedotin-4000217",
    "pregnancy": {
        "common": [
            "Based on mechanism of action and findings in animals, can cause fetal harm when administered to pregnant females",
            "Human data are not available to evaluate drug-associated risk",
            "Advise patients of potential risk to fetus and verify pregnancy status in females of reproductive potential before initiating"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Administration of MMAE (tisotumab vedotin active metabolite) to pregnant rats during organogenesis caused embryofetal mortality and structural abnormalities at exposures below the clinical exposure at the recommended dose"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 2 months after last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 4 months after last dose "
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Males: Based on findings from animal studies, may impair fertility"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available on presence in human milk, effects on breastfed children, or effects on milk production",
            "Advise lactating females not to breastfeed during treatment and for 3 weeks after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Ocular toxicity",
                    "description": [
                        "Causes changes in corneal epithelium and conjunctiva resulting in vision changes, including severe vision loss, and corneal ulceration",
                        "Conduct ophthalmic examination at baseline, prior to each dose, and as clinically indicated",
                        "Adhere to premedication and required eye care before, during, and after infusion",
                        "Withhold until improvement and resume, reduce the dose, or permanently discontinue, based on severity"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Based on mechanism of action and findings in animal studies, can cause fetal harm "
            ],
            "specific": [
                {
                    "type": "Peripheral neuropathy",
                    "description": [
                        "Peripheral neuropathy reported ",
                        "Median time to onset of peripheral neuropathy reported to be 2.4 months (range, 0-11.3 months)",
                        "Monitor for signs and symptoms of neuropathy (eg, paresthesia, tingling or burning sensation, neuropathic pain, muscle weakness, dysesthesia)",
                        "If observed, withhold dose, then reduce dose or permanently discontinue "
                    ]
                },
                {
                    "type": "Hemorrhage",
                    "description": [
                        "Hemorrhage occurred in a majority of treated patients ",
                        "Median time to onset of hemorrhage reported to be 0.3 months (range, 0-6.5 months) ",
                        "Monitor and withhold or discontinue dose as recommended"
                    ]
                },
                {
                    "type": "Pneumonitis",
                    "description": [
                        "Severe, life-threatening, or fatal pneumonitis can occur in patients treated with antibody-drug conjugates ",
                        "Pulmonary symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic examinations; infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations ",
                        "Monitor for pulmonary symptoms and adjust dose, withhold treatment, or permanently discontinue as recommended"
                    ]
                },
                {
                    "type": "Ocular adverse effects",
                    "description": [
                        "Ocular adverse reactions reported; promptly refer patients to an eye care provider for any new or worsening ocular signs and symptoms ",
                        "Conduct ophthalmic examination including visual acuity and slit lamp examination at baseline, before each dose, and as clinically indicated ",
                        "Administer premedication and cold-pack regimen with each infusion",
                        "Common ocular adverse reactions included conjunctival adverse reactions (40%), dry eye (29%), corneal adverse reactions (21%), and blepharitis (8%)",
                        "Grade 3 ocular adverse reactions occurred in 3.8%, including severe ulcerative keratitis in 3.2% of patients",
                        "One patient experienced ulcerative keratitis with perforation requiring corneal transplantation",
                        "Symblepharon was reported in patients with other tumor types treated at the recommended dose",
                        "Median time to onset of first ocular adverse reaction was 1.2 months",
                        "Among patients who experienced ocular events, 55% had complete resolution, 30% had partial improvement, 6% discontinued treatment"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Strong CYP3A4 inhibitors",
                        "Monitor closely if coadministered",
                        "Tisotumab vedotin is metabolized to monomethyl auristatin E (MMAE), a mitotic inhibitor and the cytotoxic component of the antibody-drug conjugate",
                        "MMAE is substrate of CYP3A4",
                        "Strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of tisotumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol increases and tisotumab vedotin decreases affecting hepatic/intestinal enzyme CYP3A4 metabolism. Effect of interaction is not clear, use caution. Use Caution/Monitor. Stiripentol is both an inibitor and inducer of CYP3A4. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "50"
        },
        {
            "name": "Nausea",
            "percent": "41"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "39"
        },
        {
            "name": "Alopecia",
            "percent": "39"
        },
        {
            "name": "Epistaxis",
            "percent": "39"
        },
        {
            "name": "Conjunctival adverse reactions",
            "percent": "37"
        },
        {
            "name": "Hemorrhage",
            "percent": "32"
        },
        {
            "name": "Dry eye",
            "percent": "29"
        },
        {
            "name": "Rash",
            "percent": "25"
        },
        {
            "name": "Diarrhea",
            "percent": "25"
        },
        {
            "name": "Constipation",
            "percent": "23"
        },
        {
            "name": "Abdominal pain",
            "percent": "23"
        },
        {
            "name": "Corneal adverse reactions",
            "percent": "21"
        },
        {
            "name": "Myalgia",
            "percent": "21"
        },
        {
            "name": "Vomiting",
            "percent": "17"
        },
        {
            "name": "Periorbital adverse reactions",
            "percent": "16"
        },
        {
            "name": "Pyrexia",
            "percent": "16"
        },
        {
            "name": "Arthralgia",
            "percent": "16"
        },
        {
            "name": "Decreased appetite",
            "percent": "16"
        },
        {
            "name": "Urinary tract infection",
            "percent": "14"
        },
        {
            "name": "Pain in extremity",
            "percent": "13"
        },
        {
            "name": "Pruritus",
            "percent": "13"
        },
        {
            "name": "Decreased weight",
            "percent": "12"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "52"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "42"
        },
        {
            "name": "Leukocytes decreased",
            "percent": "30"
        },
        {
            "name": "Creatinine increased",
            "percent": "29"
        },
        {
            "name": "Prothrombin INR increased",
            "percent": "26"
        },
        {
            "name": "aPTT prolonged",
            "percent": "26"
        },
        {
            "name": "ALT increased",
            "percent": "24"
        },
        {
            "name": "Lactate dehydrogenase increased",
            "percent": "22"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "21"
        },
        {
            "name": "Urate increased",
            "percent": "20"
        },
        {
            "name": "Sodium decreased",
            "percent": "20"
        },
        {
            "name": "Glucose decreased",
            "percent": "19"
        },
        {
            "name": "AST increased",
            "percent": "18"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "17"
        },
        {
            "name": "Magnesium decreased",
            "percent": "17"
        },
        {
            "name": "Creatinine kinase increased",
            "percent": "16"
        },
        {
            "name": "Albumin decreased",
            "percent": "16"
        },
        {
            "name": "Fatigue",
            "percent": "7"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "7"
        },
        {
            "name": "Hemorrhage",
            "percent": "6"
        },
        {
            "name": "Corneal adverse reactions",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Urinary tract infection",
            "percent": "2"
        },
        {
            "name": "Pain in extremity",
            "percent": "1"
        },
        {
            "name": "Decreased appetite",
            "percent": "1"
        },
        {
            "name": "Abdominal pain",
            "percent": "1"
        },
        {
            "name": "Pyrexia",
            "percent": "1"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "8"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "7"
        },
        {
            "name": "Creatinine increased",
            "percent": "4.1"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "3"
        },
        {
            "name": "Creatinine kinase increased",
            "percent": "2.1"
        },
        {
            "name": "Magnesium decreased",
            "percent": "2.1"
        },
        {
            "name": "aPTT prolonged",
            "percent": "2"
        }
    ]
}